Cronos Group Inc. to Speak at the 37th Annual Roth Conference
Cronos Group (NASDAQ: CRON) (TSX: CRON), a global cannabinoid company, has announced its participation in the upcoming 37th Annual Roth Conference. Mike Gorenstein, who serves as Chairman, President and CEO, will deliver a presentation on Monday, March 17, 2025, at 1:00 PM PT.
Investors and interested parties can access a live webcast of the presentation through the Investors section of Cronos Group's website at ir.thecronosgroup.com/events-presentations.
Cronos Group (NASDAQ: CRON) (TSX: CRON), un'azienda globale nel settore dei cannabinoidi, ha annunciato la sua partecipazione al 37° Annual Roth Conference. Mike Gorenstein, che ricopre il ruolo di Presidente, Amministratore Delegato e CEO, presenterà il suo intervento lunedì 17 marzo 2025, alle 13:00 PT.
Gli investitori e le parti interessate possono accedere a una diretta streaming della presentazione attraverso la sezione Investitori del sito web di Cronos Group all'indirizzo ir.thecronosgroup.com/events-presentations.
Cronos Group (NASDAQ: CRON) (TSX: CRON), una empresa global de cannabinoides, ha anunciado su participación en la 37ª Conferencia Anual Roth. Mike Gorenstein, quien se desempeña como Presidente, Director General y CEO, ofrecerá una presentación el lunes 17 de marzo de 2025, a la 1:00 PM PT.
Los inversores y partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección de Inversores del sitio web de Cronos Group en ir.thecronosgroup.com/events-presentations.
크로노스 그룹 (NASDAQ: CRON) (TSX: CRON), 글로벌 칸나비노이드 회사가 다가오는 제37회 연례 로스 컨퍼런스에 참여한다고 발표했습니다. 마이크 고렌스타인 회장 겸 CEO가 2025년 3월 17일 월요일 오후 1시 PT에 발표를 진행할 예정입니다.
투자자 및 관심 있는 분들은 크로노스 그룹 웹사이트의 투자자 섹션을 통해 발표의 라이브 웹캐스트에 접속할 수 있습니다: ir.thecronosgroup.com/events-presentations.
Cronos Group (NASDAQ: CRON) (TSX: CRON), une entreprise mondiale spécialisée dans les cannabinoïdes, a annoncé sa participation à la 37e Conférence Annuelle Roth. Mike Gorenstein, qui occupe le poste de Président, Directeur Général et CEO, fera une présentation le lundi 17 mars 2025, à 13h00 PT.
Les investisseurs et les parties intéressées peuvent accéder à un webcast en direct de la présentation via la section Investisseurs du site web de Cronos Group à l'adresse ir.thecronosgroup.com/events-presentations.
Cronos Group (NASDAQ: CRON) (TSX: CRON), ein globales Unternehmen im Bereich Cannabinoide, hat seine Teilnahme an der 37. jährlichen Roth-Konferenz angekündigt. Mike Gorenstein, der als Vorsitzender, Präsident und CEO tätig ist, wird am Montag, den 17. März 2025, um 13:00 Uhr PT eine Präsentation halten.
Investoren und Interessierte können über den Investorenbereich der Website von Cronos Group unter ir.thecronosgroup.com/events-presentations auf einen Live-Stream der Präsentation zugreifen.
- None.
- None.
TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at the 37th Annual Roth Conference on Monday, March 17, 2025, at 1:00 PM PT.
A live webcast will be available on the Investors section of the Company’s website at https://ir.thecronosgroup.com/events-presentations.
About Cronos Group Inc.
Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach®, PEACE NATURALS® and Lord Jones®. For more information about Cronos and its brands, please visit: thecronosgroup.com.
Forward-looking Statements
This press release may contain information that may constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, “Forward-looking Statements”). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “plan”, “anticipate”, “intend”, “potential”, “estimate”, “believe” or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include statements about Mr. Gorenstein’s intention to speak at the 37th Annual Roth Conference and Cronos’ intention to build an international iconic brand portfolio and develop disruptive intellectual property by advancing cannabis research, technology and product development. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, financial results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, which has been filed on SEDAR+ and EDGAR and can be accessed at www.sedarplus.ca and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.
Cronos Group Contact
Anna Shlimak
Investor Relations
Tel: (416) 504-0004
investor.relations@thecronosgroup.com
FAQ
When is Cronos Group (CRON) presenting at the 2025 Roth Conference?
How can investors watch Cronos Group's Roth Conference presentation?
Who will represent Cronos Group (CRON) at the 2025 Roth Conference?
What type of company is Cronos Group (CRON)?
